Dopamine receptor binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridine (HPTP), an intermediate metabolite of haloperidol

Life Sciences

Volumn 59, Issue 10, 1996, Pages 815-820

  Brand, Linda ^a   Oliver, Douglas W ^a   Van Der Schyf, Cornelis J ^a   Pond, Susan M ^b   Castagnoli Jr , Neal ^c  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

4 (4 chlorophenyl) 1 4 (4 fluorophenyl) 4 oxobutyl 1,2,3,6 tetrahydropyridine; Dopamine receptor binding; Haloperidol

Indexed keywords

4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 1,2,3,6 TETRAHYDROPYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; HALOPERIDOL; NEUROLEPTIC AGENT; RADIOLIGAND; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALIA;

EID: 0030564890     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00372-4     Document Type: Article

References (17)

1. 1. R.J. BALDESSARINI. The Pharmacological Basis of Therapeutics, A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds), 383-435, Pergamon Press, New York (1991).
2. 2. B.A. ELLENBROEK. Pharmacol. Ther., 57 1-78 (1993).
3. 3. P. SEEMAN. Pharmacol. Rev., 32 229-313 (1981).
4. 4. D.E. CASEY. Curr. Opin. Psychiatry, 4 86-89 (1991).
5. 5. J. KORNHUBER, P.I. RIEDERER, G.P. REYNOLDS, H. BECKMANN, K. JELLINGER and E. GABRIEL. J. Neural. Transm., 75 1-10 (1989).
6. 6. W.M. GLAZER, D.C. MOORE, N.R. SCHOOLER, L.M. BRENNER & H. MORGENSTERN. Arch. Gen. Psychiatry, 42 623-627 (1984).
7. 7. J. FANG and J.W. GORROD. Toxicol. Lett., 59 117-123 (1991).
8. 8. J. FANG, P.H. Yu, J.W. GORROD and A.A. BOULTON. Psychopharmacol., 118 206-212 (1995).
9. 9. D.W. EYLES, H.R. MCLENNAN, A. JONES, J.J. MCGRATH, T.J. STEDMAN and S.M. POND. Clin. Pharmacol. Ther., 56 512-520 (1994).
10. 10. B. SUBRAMANYAM, S.M. POND, D.W. EYLES, H.A. WHITEFORD, H.G. FOUDA and N. CASTAGNOLI, JR. Biochem. Biophys. Res. Commun, 181 573-578 (1991).
11. 11. B. SUBRAMANYAM, T. WOOLF and N. CASTAGNOLI, JR. Chem. Res. Toxicol., 4 123-128 (1991).
12. 12. C.J. VAN DER SCHYF, K. CASTAGNOLI, E. USUKI, H.G. FOUDA, J..M. RIMOLDI and N. CASTAGNOLI, JR. Chem. Res. Toxicol., 7 281-285 (1994).
13. 13. C.E. KELLER, P.A. KARR, M.E. ZANDLER and W.R. CARPER. Struct. Chem., 3 195-201 (1992).
14. 14. W. BILLARD, V. RUPERTO, G. CROSBY, L.C. IORIO and A. BARNETT. Life Sci., 35 1885-1893 (1984).
15. 15. O.H. LOWRY, N.J. ROSEBROUGH, A.L. FARR and R.J. RANDALL. J. Biol. Chem., 193 265-275 (1951).
16. 16. Y-C. CHENG and W.H PRUSOFF. Biochem. Pharmacol., 22 3099-3108 (1973).
17. 17. I. CREESE, D.R. SIBLEY and S.E. LEFF. Federation Proc., 43 2779-2784 (1984).